Allergy Therapeutics plc (LON:AGY) had its target price increased by FinnCap from GBX 43 ($0.56) to GBX 46 ($0.60) in a report published on Tuesday, July 18th. FinnCap currently has a buy rating on the stock.
AGY has been the topic of a number of other research reports. Panmure Gordon restated a buy rating and issued a GBX 53 ($0.69) target price on shares of Allergy Therapeutics plc in a research note on Thursday, April 20th. Numis Securities Ltd boosted their target price on Allergy Therapeutics plc from GBX 37 ($0.48) to GBX 45 ($0.59) and gave the company a buy rating in a research note on Tuesday, April 4th. Finally, Stifel Nicolaus restated a buy rating and issued a GBX 60 ($0.78) target price on shares of Allergy Therapeutics plc in a research note on Tuesday, April 4th.
Shares of Allergy Therapeutics plc (AGY) traded down 1.69% during mid-day trading on Tuesday, reaching GBX 29.00. The company’s stock had a trading volume of 101,757 shares. Allergy Therapeutics plc has a 52-week low of GBX 17.25 and a 52-week high of GBX 32.00. The company’s market capitalization is GBX 172.10 million. The firm’s 50 day moving average is GBX 27.83 and its 200-day moving average is GBX 26.92.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Stock Observer and is the sole property of of Stock Observer. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.thestockobserver.com/2017/08/12/allergy-therapeutics-plc-lonagy-price-target-raised-to-gbx-46-updated-updated-updated.html.
Allergy Therapeutics plc Company Profile
Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.